Ashford Capital Management Inc. Invests $3.26 Million in ADMA Biologics Inc $ADMA

Ashford Capital Management Inc. bought a new stake in shares of ADMA Biologics Inc (NASDAQ:ADMA) during the 1st quarter, HoldingsChannel reports. The institutional investor bought 361,500 shares of the biotechnology company’s stock, valued at approximately $3,257,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of ADMA. Janus Henderson Group PLC boosted its stake in ADMA Biologics by 3,906.1% during the fourth quarter. Janus Henderson Group PLC now owns 3,936,419 shares of the biotechnology company’s stock worth $71,820,000 after buying an additional 3,838,158 shares during the period. Capital Research Global Investors raised its stake in shares of ADMA Biologics by 104.0% in the fourth quarter. Capital Research Global Investors now owns 6,637,472 shares of the biotechnology company’s stock valued at $121,067,000 after acquiring an additional 3,383,559 shares during the period. Caligan Partners LP purchased a new stake in shares of ADMA Biologics in the third quarter valued at $38,653,000. UBS Group AG lifted its holdings in shares of ADMA Biologics by 129.9% in the 4th quarter. UBS Group AG now owns 4,569,343 shares of the biotechnology company’s stock worth $83,345,000 after acquiring an additional 2,581,670 shares during the last quarter. Finally, Sachem Head Capital Management LP lifted its holdings in shares of ADMA Biologics by 27.0% in the 4th quarter. Sachem Head Capital Management LP now owns 11,375,000 shares of the biotechnology company’s stock worth $207,480,000 after acquiring an additional 2,415,000 shares during the last quarter. Hedge funds and other institutional investors own 75.68% of the company’s stock.

Insider Buying and Selling at ADMA Biologics

In related news, Director Jerrold B. Grossman purchased 12,500 shares of the firm’s stock in a transaction dated Monday, May 11th. The stock was purchased at an average price of $8.01 per share, with a total value of $100,125.00. Following the completion of the purchase, the director owned 513,884 shares of the company’s stock, valued at approximately $4,116,210.84. The trade was a 2.49% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 3.90% of the company’s stock.

ADMA Biologics Trading Up 2.5%

ADMA stock opened at $8.48 on Tuesday. ADMA Biologics Inc has a 12 month low of $7.21 and a 12 month high of $20.46. The firm’s 50-day moving average is $8.48 and its 200 day moving average is $11.83. The company has a market capitalization of $1.97 billion, a PE ratio of 12.47 and a beta of 0.73. The company has a debt-to-equity ratio of 0.51, a current ratio of 6.95 and a quick ratio of 3.93.

ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $0.19 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.19. The company had revenue of $114.49 million during the quarter, compared to analysts’ expectations of $139.98 million. ADMA Biologics had a net margin of 32.43% and a return on equity of 39.98%. The firm’s quarterly revenue was down .3% on a year-over-year basis. During the same period in the previous year, the company earned $0.11 EPS. On average, research analysts anticipate that ADMA Biologics Inc will post 0.8 EPS for the current year.

Key Stories Impacting ADMA Biologics

Here are the key news stories impacting ADMA Biologics this week:

• Positive Sentiment: Brokerages reportedly maintain a consensus price target of $18.67, substantially above ADMA’s recent trading level. This indicates that analysts see potential upside despite the company’s recent decline from its 52-week high. ADMA Biologics Receives $18.67 Consensus Price Target
• Neutral Sentiment: ADMA’s latest session ended higher and ahead of the market, with trading activity near its normal volume. The report primarily describes the stock’s performance and does not identify a new fundamental catalyst. ADMA Biologics Rises Higher Than Market
• Negative Sentiment: Several law firms publicized a securities class action against ADMA and certain executives, with an August 10, 2026 deadline for investors to seek lead-plaintiff status. The complaints allege misleading statements involving financial condition, revenue recognition, inventory distribution and business practices. These are allegations and have not been proven in court. ADMA Securities Fraud Class Action Alert
• Negative Sentiment: One complaint alleges ADMA shipped unwanted ASCENIV inventory to distributors at $900 per gram, creating artificial demand while payors denied reimbursement and providers reduced orders. If substantiated, the claims could raise concerns about revenue quality, inventory levels, regulatory exposure and potential financial liability. ADMA Shareholder Alert

Analyst Ratings Changes

A number of research firms recently commented on ADMA. Wall Street Zen cut shares of ADMA Biologics from a “buy” rating to a “hold” rating in a research note on Monday, May 4th. Canaccord Genuity Group reduced their price objective on shares of ADMA Biologics from $21.00 to $18.00 and set a “buy” rating on the stock in a research report on Thursday, May 7th. Weiss Ratings reissued a “hold (c)” rating on shares of ADMA Biologics in a research note on Thursday, June 18th. Raymond James Financial initiated coverage on ADMA Biologics in a research report on Wednesday, June 10th. They set an “outperform” rating and a $21.00 target price for the company. Finally, Mizuho cut their target price on ADMA Biologics from $20.00 to $17.00 and set an “outperform” rating on the stock in a research note on Wednesday, July 15th. Three research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $18.67.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.